EULAR definition of difficult-to-treat rheumatoid arthritis

被引:304
|
作者
Nagy, Gyorgy [1 ,2 ]
Roodenrijs, Nadia M. T. [3 ]
Welsing, Paco M. J. [3 ]
Kedves, Melinda [4 ]
Hamar, Attila [5 ]
van der Goes, Marlies C. [3 ,6 ]
Kent, Alison [7 ]
Bakkers, Margot [8 ]
Blaas, Etienne [3 ]
Senolt, Ladislav [9 ,10 ]
Szekanecz, Zoltan [5 ]
Choy, Ernest [11 ]
Dougados, Maxime [12 ]
Jacobs, Johannes W. G. [3 ]
Geenen, Rinie [13 ]
Bijlsma, Hans W. J. [3 ]
Zink, Angela [14 ,15 ]
Aletaha, Daniel [16 ]
Schoneveld, Leonard [17 ]
van Riel, Piet [18 ]
Gutermann, Loriane [19 ]
Prior, Yeliz [20 ]
Nikiphorou, Elena [21 ]
Ferraccioli, Gianfranco [22 ]
Schett, Georg [23 ,24 ]
Hyrich, Kimme L. [25 ,26 ]
Mueller-Ladner, Ulf [27 ]
Buch, Maya H. [25 ,26 ,28 ]
McInnes, Iain B. [29 ]
van der Heijde, Desiree [30 ]
van Laar, Jacob M. [3 ]
机构
[1] Semmelweis Univ, Dept Rheumatol, Dept Internal Med 3, Budapest, Hungary
[2] Semmelweis Univ, Dept Genet Cell & Immunobiol, Budapest, Hungary
[3] Univ Utrecht, Univ Med Ctr Utrecht, Dept Rheumatol & Clin Immunol, Utrecht, Netherlands
[4] Bacs Kiskun Cty Hosp, Dept Rheumatol, Kecskemet, Hungary
[5] Univ Debrecen, Fac Med, Dept Rheumatol, Debrecen, Hungary
[6] Meander Med Ctr, Dept Rheumatol, Amersfoort, Netherlands
[7] Salisbury Fdn Trust NHS Hosp, Salisbury, Wilts, England
[8] EULAR Standing Comm People Arthrit Rheumatism Eur, Zurich, Switzerland
[9] Charles Univ Prague, Fac Med 1, Dept Rheumatol, Prague, Czech Republic
[10] Inst Rheumatol, Prague, Czech Republic
[11] Cardiff Univ, CREATE Ctr, Sch Med, Sect Rheumatol,Div Infect & Immun, Cardiff, Wales
[12] Univ Paris, Hop Cochin, AP HP,Clin Epidemiol & Biostat, Dept Rheumatol,PRES Sorbonne Paris Cite,INSERM,U1, Paris, France
[13] Univ Utrecht, Dept Psychol, Utrecht, Netherlands
[14] Univ Med, Charite, Epidemiol Unit, German Rheumatism Res Ctr, Berlin, Germany
[15] Univ Med, Charite, Rheumatol, Berlin, Germany
[16] Med Univ Vienna, Div Rheumatol, Dept Internal Med 3, Vienna, Austria
[17] Bravis Hosp, Dept Rheumatol, Roosendaal, Netherlands
[18] Radboud Univ Nijmegen, Med Ctr, Dept Rheumat Dis, Nijmegen, Netherlands
[19] Paris Descartes Univ, Hop Cochin, AP HP, Dept Pharm, Paris, France
[20] Univ Salford, Ctr Hlth Sci Res, Sch Hlth & Soc, Salford, Lancs, England
[21] Kings Coll London, Ctr Rheumat Dis, London, England
[22] Univ Cattolica Sacro Cuore, Sch Med, Rome, Italy
[23] Friedrich Alexander Univ Erlangen Nuremberg, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany
[24] Univ Klinikum Erlangen, Erlangen, Germany
[25] Cent Manchester NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, NIHR Manchester Musculoskeletal Biomed Res Unit, Manchester, Lancs, England
[26] Univ Manchester, Sch Biol Sci, Fac Biol Med & Hlth, Ctr Musculoskeletal Res, Manchester, Lancs, England
[27] Justus Liebig Univ Giessen, Kerckhoff Clin Bad Nauhe, Dept Rheumatol & Clin Immunol, Bad Nauheim, Germany
[28] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[29] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland
[30] Leiden Univ, Dept Rheumatol, Med Ctr, Leiden, Netherlands
关键词
RECOMMENDATIONS;
D O I
10.1136/annrheumdis-2020-217344
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be considered to have 'difficult-to-treat RA'. However, uniform terminology and an appropriate definition are lacking. Objective The Task Force in charge of the "Development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis" aims to create recommendations for this underserved patient group. Herein, we present the definition of difficult-to-treat RA, as the first step. Methods The Steering Committee drafted a definition with suggested terminology based on an international survey among rheumatologists. This was discussed and amended by the Task Force, including rheumatologists, nurses, health professionals and patients, at a face-to-face meeting until sufficient agreement was reached (assessed through voting). Results The following three criteria were agreed by all Task Force members as mandatory elements of the definition of difficult-to-treat RA: (1) Treatment according to European League Against Rheumatism (EULAR) recommendation and failure of >= 2 biological disease-modifying antirheumatic drugs (DMARDs)/targeted synthetic DMARDs (with different mechanisms of action) after failing conventional synthetic DMARD therapy (unless contraindicated); (2) presence of at least one of the following: at least moderate disease activity; signs and/or symptoms suggestive of active disease; inability to taper glucocorticoid treatment; rapid radiographic progression; RA symptoms that are causing a reduction in quality of life; and (3) the management of signs and/or symptoms is perceived as problematic by the rheumatologist and/or the patient. Conclusions The proposed EULAR definition for difficult-to-treat RA can be used in clinical practice, clinical trials and can form a basis for future research.
引用
收藏
页码:31 / 35
页数:5
相关论文
共 50 条
  • [11] CHARACTERISTICS OF DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS
    Takanashi, S.
    Kaneko, Y.
    Takeuchi, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 612 - 613
  • [12] DIAGNOSTIC ISSUES IN DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS: THE UTILITY OF ULTRASOUND IN STANDARD PRACTICE FOR DIFFICULT TO TREAT RHEUMATOID ARTHRITIS
    Elwakil, W.
    El Miedany, Y.
    Abu-Zaid, M. H.
    Elgaafary, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2024, 83
  • [13] Is Baricitinib Effective and Safe for Patients with Difficult-to-Treat Rheumatoid Arthritis? Comparative Data with the Rheumatoid Arthritis Group of Rheumatoid Arthritis Not Difficult to Treat
    Ekin, Ali
    Misirci, Salim
    Gorunen, Ahmet
    Coskun, Belkis Nihan
    Yagiz, Burcu
    Dalkilic, Ediz
    Pehlivan, Yavuz
    MEDICAL PRINCIPLES AND PRACTICE, 2025, 34 (01) : 75 - 86
  • [14] STRATEGIES REGARDING GOAL SETTING AND SELF-MANAGEMENT IN DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2020 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS
    Roodenrijs, N. M. T.
    Hamar, A.
    Kedves, M.
    Nagy, G.
    Van Laar, J. M.
    Van der Heijde, D.
    Welsing, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 595 - 595
  • [15] A Closer Look at the Difficult-to-Treat Rheumatoid Arthritis Patients
    Gazel, Ummugulsum
    Acikgoz, Seyyid
    Chowdhury, Rokhsana
    Ivory, Catherine
    Zahrai, Amin
    Hepworth, Elliot
    Aydin, Sibel
    JOURNAL OF RHEUMATOLOGY, 2023, 50 (07) : 43 - 44
  • [16] Difficult-to-Treat Rheumatoid Arthritis: Challenges in Diagnosis and Treatment
    Shouval, Aniela
    Keret, Shiri
    Rosner, Itzhak
    Slobodin, Gleb
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2024, 26 (09): : 522 - 528
  • [17] Gut dysbiosis is associated with difficult-to-treat rheumatoid arthritis
    Ruiz-Limon, Patricia
    Mena-Vazquez, Natalia
    Moreno-Indias, Isabel
    Lisbona-Montanez, Jose Manuel
    Mucientes, Arkaitz
    Manrique-Arija, Sara
    Redondo-Rodriguez, Rocio
    Cano-Garcia, Laura
    Tinahones, Francisco J.
    Fernandez-Nebro, Antonio
    FRONTIERS IN MEDICINE, 2025, 11
  • [18] CHARACTERISTICS OF PATIENTS WITH DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS IN FRANCE
    Hecquet, S.
    Combier, A.
    Steelandt, A.
    Pons, M.
    Wendling, D.
    Molto, A.
    Richard, C. Miceli
    Allanore, Y.
    Avouac, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 181 - 182
  • [19] PROFILING OF CIRCULATING MIRNAS IN DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS
    Baloun, J.
    Pekacova, A.
    Mann, H.
    Vencovsky, J.
    Pavelka, K.
    Senolt, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 477 - 477
  • [20] Characteristics and Evolution of Patients With Difficult-to-treat Rheumatoid Arthritis
    Qi, Wen
    Robert, Antoine
    Singbo, Narcisse
    Ratelle, Lucie
    Bessette, Louis
    Fortin, Paul
    Brown, Jacques
    Michou, Laetitia
    JOURNAL OF RHEUMATOLOGY, 2022, 49 (07) : 758 - 758